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ABSTRACT
Objective: It was proposed to determine the chromosomal abnormalities in a 49-year-old male patient with multiple myeloma (MM) employing both 
conventional and advanced molecular cytogenetic techniques.
Methods: GTG-banding and spectral karyotyping (SKY) on fixed metaphases obtained from LPS-stimulated bone marrow cells and interphase 
fluorescence in situ hybridization (iFISH) on unsorted marrow cells were carried out to identify genetic markers of prognostic significance.
Results: The abnormal chromosomes observed through conventional cytogenetics could be resolved with SKY technique. The translocation t(4;14)
(p16;q32) indicating FGFR3/IGH fusion and deletion of 13q14.3 was noticed using iFISH. The genetic abnormalities confirmed a poor prognostic 
outcome in the patient who died within 6 months of diagnosis.
Conclusion: This report emphasizes the need for multicolor FISH techniques besides iFISH to resolve complex abnormalities and to identify cryptic 
aberrations of importance in risk stratification of MM patients.
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INTRODUCTION
Multiple myeloma (MM) is a clinically and genetically heterogeneous 
hematopoietic neoplasm of plasma cells characterized by their 
accumulation in the bone marrow, production of excessive monoclonal 
immunoglobulin (M or myeloma protein) in serum and urine, and 
osteolytic bone lesions. These features lead to pathological bone fragility, 
nephropathy, immunodeficiency, and hematopoietic disorders [1]. 
Genetic abnormalities are almost always present in MM patients although 
an abnormal karyotype can be detected using conventional Giemsa-
banding techniques in only 25–35% of them [2]. The low proliferation 
index of plasma cells and the poor morphology of chromosomes pose 
additional problems [3]. Analysis with fluorescence in situ hybridization 
on interphase nuclei (iFISH) using chromosome-specific alpha 
satellite DNA probes confirmed hyperdiploidy, locus-specific probes 
demonstrated microdeletions, and dual-fusion probes identified cryptic 
chromosomal translocations involving the immunoglobulin heavy chain 
(IGH) gene in 14q32.3 such as t(4;14) [4,5]. Guidelines to perform iFISH 
on plasma cells selected based on morphology, immunophenotyping, or 
sorting are available [3,6,7].
Non-random chromosome abnormalities of prognostic significance 
detected by iFISH help to stratify patients into two main groups - (1) 
the hyperdiploid MM having trisomies of odd-numbered chromosomes 
3, 5, 7, 9, 11, 15, 19, and 21 and (2) the non-hyperdiploid MM including 
translocations involving the IGH gene such as t(11;14)(q13;q32), 
t(4;14)(p16;q32), and t(14;16)(q32;q23) in a majority of the cases. 
Monosomy 13/del(13q), del(17p), and deletion of 1p or amplification 
of 1q are commonly associated with aggressive disease [5]. With the 
advent of advanced molecular cytogenetic techniques such as multicolor 
fluorescence in situ hybridization (M-FISH) and spectral karyotyping 
(SKY) which allowed a simultaneous unequivocal identification of all 
the 24 chromosomes, it was possible to unambiguously characterize 
complex rearrangements and identify the chromosomal origin of 
marker chromosomes [2,8-10]. However, cytogenetic data employing 
these methodologies on MM are scarce because of the low mitotic 
activity of plasma cells, heterogeneity within the clonal population, the 
technical pitfalls during interpretation of results, and their restricted 
availability [2,11]. This report describes the application of SKY in the 
characterization of complex chromosomal abnormalities detected in a 
newly diagnosed MM patient.
CASE REPORT
A 49-year-old north Indian man was evaluated at the Department of 
Hematology, Apollo Hospitals, Chennai-6, in November 2012 for a 
2-month history of loss of appetite and severe pain in the back and 
legs. He was involved in agricultural pesticide business. His medical 
reports indicated hypercalcemia, systemic hypertension, and azotemia. 
He was a non-smoker and a teetotaler with no family history of cancer. 
Trephine biopsy section showed trabeculae of bone with intervening 
hypercellular marrow particles. There was a diffuse infiltration of 
atypical plasma cells and mitosis was increased. Immunofixation 
electrophoresis showed monotypic expression of the immunoglobulin 
A heavy and lambda light chains. Laboratory investigations revealed 
platelet count to be 40,000 cells/cu mm, and peripheral smear study 
showed intense rouleaux formation. Bone marrow cytology was 
particulate with blood-diluted cell trail and intense plasmacytosis (80% 
plasma cells). Biochemical investigations showed serum creatinine 
1.1 mg/dL, calcium 15.6 mg/dL, serum albumin/globulin reversal, 
and β2-microglobulin 5.6mg/L. These findings were consistent with 
MM. He was started on dexamethasone and bortezomib along with 
supportive measures. Follow-up studies revealed that the patient had 
expired within 6 months.
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This study was approved by the institutional ethics committee. 
Detailed case history and bone marrow sample were collected after 
written informed consent was obtained from the patient. Chromosomal 
preparations were obtained from unsorted, lipopolysaccharide 
(Sigma-Aldrich)-stimulated bone marrow cells and were GTG-
banded following standard protocols. About 25 metaphases were 
karyotyped using applied spectral imaging (ASI) systems karyotyping 
software (Band View version 6.0). Chromosomal anomalies were 
designated using standard nomenclature. SKY was performed using 
the same fixed chromosome preparations employing 24-color 
combinatorically labeled SKYPaint® Probes (ASI Inc., CA) according 
to manufacturer’s instructions. The images were captured using an 
epifluorescence microscope equipped with a CCD camera. A total of 
30 metaphases were analyzed and the breakpoints were determined 
by comparison with corresponding DAPI-banded chromosomes. The 
iFISH procedure was carried out on unsorted bone marrow cells 
fixed on slides employing seven commercially available probes for 
MM following manufacturer’s specifications. About 300 interphase 
nuclei were scored for the presence of signals for each probe. Images 
were captured under respective filters in Olympus BX-51 microscope 
(Olympus, Tokyo, Japan) and analysis was done with the ASI systems 
software (FISH View version 6.0).
Analysis of GTG-banded metaphases showed a hyperdiploid karyotype 
with several abnormal chromosomes (Fig. 1a). SKY revealed these 
derivative chromosomes to result from complex translocations besides 
cryptic rearrangements in 24 of 30 metaphases (Fig. 1b).
The translocation t(4;14)(p16;q32) was inferred from iFISH using IGH 
break apart and fibroblast growth factor receptor 3 (FGFR3)/IGH dual-
fusion probes (Fig. 2a-d). The probe LSI D13S319 (13q14.3) showed 
monoallelic deletion of 13q14.3 locus while the CEP9 probe identified 
trisomy 9 (Fig. 2e-f).
The IGH break-apart probe showed a typical pattern in 40% of nuclei 
scored while an extra 5’ signal was seen in 35% indicating clonal 
evolution. In concurrence, a classical fusion pattern and an extra fusion 
signal were observed in 40% and 35% of cells, respectively, with the 
FGFR3-IGH probe.
DISCUSSION
MM is a clonal malignancy of differentiated B-cells with acquired genetic 
abnormalities of clinical importance unidentifiable by conventional 
cytogenetic analysis. Smol and Daudignon [12] compared IGH signal 
patterns using FGFR3-IGH dual-color, dual-fusion translocation probe, 
and IGH dual-color break-apart probe in 49 patients with MM. The 
t(4;14) translocation seen in 26% of cases was observed to be associated 
with multiple presentations of IGH, namely a loss or gain of the IGH 
locus and a deletion of the IGH variable segment. He et al. [13] reported 
several patterns of IGH deletion including monoallelic loss of whole IGH 
locus, monoallelic deletion of 3’IGH or 5’IGH and biallelic deletion of 
3’IGH. Further, the authors observed IGH deletions to be more frequent 
with 13q deletion and without t(4;14). Our proband showed t(4;14) 
translocation along with 13q deletion but without IGH deletion. In 
addition, a gain of 5’IGH variable segment was observed in the evolving 
sideline. The very high association of del(13q) abnormalities in t(4;14) 
patients and not vice versa led to the suggestion that chromosome 
13 abnormalities precede the translocation [11,14]. Acquisition of 
additional abnormalities may reflect an underlying active or genetically 
b
Fig. 1: (a) GTG-banded karyotype: 47,X,+der(X),-Y,del(1q), del(2)
(p11),+3,del(8q),+2r(8),+der(9),der(12),-13,der(15), 
der(16),der(18),-19,-21,der(22) [arrows indicate abnormal 






Fig. 2: Dual color IGH break-apart probe on interphase cells 
showing the pattern (a) F1G1R1 and (b) F1G2R1; LSI IGH-FGFR3 
dual-fusion probe showing (c) F2G1R1 and (d) F3G1R1,  
(e) LSI D13S19 (13q14.3)/13q34 probe showing monoallelic 
deletion of locus 13q14.3 (one red signal) and two copies of locus 
13q34 (two green signals); (f) CEP 9 probe exhibiting trisomy  






Asian J Pharm Clin Res, Vol 11, Issue 9, 2018, 9-11
 Govindasamy et al. 
unstable clone driving the disease process at that point [15]. The 
translocation in association with del(13q) and complex chromosomal 
rearrangements denoted a poor prognosis in our patient who died 
within 6 months of diagnosis.
Application of SKY in our patient did not reveal the subtle t(4;14) 
translocation as in earlier reports describing new recurring 
translocations [8,16]. However, SKY could clarify the derivative 
chromosomes and confirm the numerical aberrations. Multicolor 
FISH techniques such as M-FISH and SKY provided improved 
characterization of complex and ill-defined karyotypes [2,3,8,9]. 
Sawyer et al. [9] using SKY identifying gain of 1q and loss of 8p 
frequently pointed out the importance of secondary aberrations 
in the progression of the disease. Several reports are available on 
the usefulness of SKY technique in the comprehensive analysis 
of chromosomes in hematopoietic disorders [17-19]. SKY will 
definitely serve as an adjunct to the conventional G-banding and 
iFISH techniques and aid in the identification of novel recurrent 
abnormalities in MM.
CONCLUSION
A complex karyotype denotes rapid tumor progression, and the 
prognostic significance of individual abnormalities will be known 
through extended analysis over a larger sample size on confirmation 
using emerging technologies such as targeted next-generation 
sequencing.
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